Bibliographic Details
| Title: |
Association of early therapeutic drug monitoring of adalimumab with biologic remission and drug survival in Crohn’s Disease |
| Authors: |
José Luis Rueda García, Cristina Suárez-Ferrer, Clara Amiama Roig, Laura García Ramírez, Cristina García Rojas, Eduardo Martín-Arranz, Joaquín Poza Cordón, María Sánchez Azofra, Jesús Noci, Cristina Cubillo García, María Dolores Martín-Arranz |
| Source: |
Therapeutic Advances in Gastroenterology, Vol 18 (2025) |
| Publisher Information: |
SAGE Publishing, 2025. |
| Publication Year: |
2025 |
| Collection: |
LCC:Diseases of the digestive system. Gastroenterology |
| Subject Terms: |
Diseases of the digestive system. Gastroenterology, RC799-869 |
| More Details: |
Background: Therapeutic drug monitoring of adalimumab (ADA) is still controversial. Objectives: To study the association between ADA trough levels in the early stages of treatment with biological remission (BR) and drug survival in Crohn’s disease (CD). Design: Retrospective cohort study. Methods: Patients treated with ADA with available trough levels at weeks 2 and 6 (after the first induction and maintenance dose, respectively) were included. Fecal calprotectin (Fcal) and C-reactive protein (CRP) were registered at baseline, week 24, and week 52. BR was defined as Fcal 12.27 μg/ml predicted BR at week 24 with 79.7% specificity and 79.5% positive predictive value. Patients in the third quartile (Q3) and fourth quartile (Q4) of ADA levels at week 6 exhibited higher rates of BR at week 24, BR at week 52, 1-year drug survival, and less need for dose escalation (all p -values |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1756-2848
17562848 |
| Relation: |
https://doaj.org/toc/1756-2848 |
| DOI: |
10.1177/17562848251324226 |
| Access URL: |
https://doaj.org/article/620b8e08575c430e9aa16fba1421ce94 |
| Accession Number: |
edsdoj.620b8e08575c430e9aa16fba1421ce94 |
| Database: |
Directory of Open Access Journals |
